Rational Dispersion of Novel Technologies & the Need for Additional Evidence Generation: Lessons Learned from Recent CMS NCDs

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Abbott; Boston Scientific Corporation; Cytokinetics; Edwards Lifesciences</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Medtronic; Boehringer Ingelheim; Veralox Therapeutics; AstraZenca; Premiere; Abbott; Edwards Lifesciences; cytokinetics</li></ul>